ANN ARBOR – Genomenon has struck a co-marketing agreement with Fluidigm Corp. to offer evidence-based genomic panel design services for translational and clinical disease research.
Through the Fluidigm-Genomenon joint panel design services offering, researchers will be able to accelerate the design of disease-specific next-generation sequencing, genotyping, and real-time PCR panels for use with highly efficient Fluidigm automated microfluidic systems.
“Starting with any target set of diseases, Fluidigm and Genomenon together can provide an expert-level gene panel in record time,” said Mike Klein, CEO of Genomenon. “We’ve proven the model with a number of NGS panels in collaboration with Fluidigm and are excited to open this up to custom designs for Fluidigm customers.”
The Genomenon Mastermind Panel Design Service is designed to meet this challenge by identifying disease-specific biomarkers for researchers using its proprietary Mastermind genomic search database and automated machine learning algorithms. The Genomenon team then curates the biomarkers based on the strength and quality of the scientific evidence found in the literature and delivers a set of prioritized candidates to researchers to aid in panel design.
“We are very excited to announce our relationship with Genomenon to accelerate the design of high-value disease-specific panels both for our customers and in our own internal assay design pipeline,” said Chris Linthwaite, President and CEO of Fluidigm. “This valuable addition to our custom genomic panel design offering represents an important building block in expanding the benefits of microfluidics technology to a wider range of disease research areas.”
For more information, visit www.genomenon.com.
